Investment in Rafael Pharmaceuticals (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Jan. 31, 2019	Jan. 31, 2020
Pharma Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Textual)
Ownership percentage in non-operating subsidiary		50.00%
Howard Jonas [Member] | CS Pharma Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Textual)
Indirect interest in assets held, percentage		45.00%
Ownership interest, percentage		10.00%
IDT-Rafael Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Textual)
Fully diluted		51.00%
Bonus shares		38.00%
IDT-Rafael Holdings, LLC [Member] | Series D Convertible Preferred Stock [Member]
Investment in Rafael Pharmaceuticals (Textual)
Warrants expiry date		Dec. 31, 2020
Exercise price of warrants or rights, description		Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase the collective ownership of Pharma Holdings and CS Pharma to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share.
Purchase of exercise the warrant, shares		16,700,000
Exercise of warrants purchases, description		The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution, winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.
CS Pharma Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Textual)
Ownership percentage in non-operating subsidiary		90.00%
Indirect interest in assets held, percentage		45.00%
Ownership interest, percentage		50.00%
CS Pharma Holdings, LLC [Member] | Series D Convertible [Member]
Investment in Rafael Pharmaceuticals (Textual)
Convertible promissory note, rate of interest	3.50%
Principal amount	$ 10,000